-
Popular cough syrup recalled over contamination
Haleon, the maker of Robitussin, has issued a voluntary recall of eight lots of three varieties of its cough medicines due to microbial contamination. -
Fake Ozempic tied to 3 cases of hypoglycemia: Reuters
A regional poison control center suspects three cases of hypoglycemia in 2023 were linked to counterfeit versions of Ozempic, according to a Jan. 24 Reuters exclusive report. -
Judge upholds Martin Shkreli's lifetime pharma ban
A federal appeals court in New York has upheld an order that bars "pharma bro" Martin Shkreli from working in the pharmaceutical industry, according to court documents. -
Tyson replaces CVS with Rightway for pharmacy benefits
CVS Caremark will no longer handle pharmacy costs for Tyson Foods' 140,000 employees after the company cut its contract, CNBC reported Jan. 24. A few months ago, Blue Shield California curbed its yearslong partnership with the pharmacy benefit manager. -
Majority of patients maintain weight loss after stopping medication, study reveals
After discontinuing the use of semaglutide and liraglutide weight-loss medications, a majority of patients were able to maintain the same weight they were at when halting the use — or even continued to lose additional weight after one year, a new study revealed. -
How the Ozempic boom affects hospital pharmacies
The viral popularity of Ozempic, Wegovy, and other diabetes and weight loss drugs is affecting hospital operations in a roundabout way. -
FDA calls for warning labels on commercial CAR-T therapies amid cancer probe
The FDA is now calling for warning labels on all commercial CAR-T therapy products amid its investigation into 22 reports about a possible being linked to lymphoma. -
Corrections made in ongoing FDA eye drop recall
The FDA has published corrections and additions to a company's voluntary recall of eye drops after a wave of several others throughout 2023. -
Washington pharmacists prepare to prescribe abortion pills
A handful of pharmacists in Washington state are training to prescribe the abortion medication mifepristone, NPR reported Jan. 22. -
Maryland system reduces opioid scripts by 55%
Over the last five years, Hagerstown, Md.-based Meritus Health cut the number of opiates prescribed by more than 55% in its effort to quell the national opioid epidemic. -
Drug shortages group elects 3 pharmacy leaders to board
The End Drug Shortages Alliance appointed Terri Lyle Wilson as its new chair and appointed two board members Jan. 23. -
North Carolina state health plan drops weight loss drug coverage; to incur $54M rebate loss
North Carolina's state health plan dropped new coverage for weight loss drugs Jan. 1, a decision that is expected to cost the state $54 million in lost drug rebates, WRAL News reported Jan. 12. -
Some BCBS plans cover new sickle cell gene therapies
Some Blue Cross Blue Shield companies now cover two newly approved sickle cell gene therapies, which cost about $2 million and $3 million per dose. -
FDA finds deficiencies at Eli Lilly plant: Reuters
During a visit last summer, FDA inspectors flagged eight deficiencies at an Eli Lilly manufacturing plant in Branchburg, N.J., according to an inspection report Reuters obtained through a Freedom of Information Act Request. -
Drugmakers explore muscle loss prevention when taking weight loss drugs
Despite their rise to popularity as solutions for weight loss, drugs like Ozempic and Wegovy can also lead to muscle loss, and now pharmaceutical companies are looking at ways to curb the unwanted side effect, according to The Wall Street Journal. -
'Faux-zempic': What to know about compounded weight loss drugs
Physicians, drugmakers, obesity organizations and the FDA are fretting about compounded versions of popular weight loss and diabetes drugs, including Wegovy, Ozempic and Zepbound. -
Children's National Hospital taps Clearway to deliver $2.8M gene therapy
Washington, D.C.-based Children's National Hospital administered Zynteglo, a $2.8 million gene therapy, to its first pediatric patient with the help of Clearway Health. -
FDA adds severe risk warning to bone disease drug
The bone disease drug Prolia has a new boxed warning, the FDA's most prominent warning, because of an increased risk of severe hypocalcemia among chronic kidney disease patients. -
Nitrosamine measures might disrupt anesthetic supply, Dr. Eric Tichy says
Hospitals should start conserving supply of short-term anesthetics as drug manufacturers become more conservative with nitrosamine measures, according to Eric Tichy, PharmD. -
Pharmacist becomes Philadelphia hospital CEO
Former health system pharmacy leader Shawn Parekh, PharmD, recently became CEO of a Philadelphia hospital.
Page 11 of 50